Biotechnology company Creative Medical Technology Holdings, Inc. seems to be witnessing success in the allogeneic cell therapy market. 

In Q4 2022, the company – best known for its regenerative approach to immunotherapy, endocrinology, urology, gynecology and orthopedics – made a significant announcement regarding the successful development of an allogeneic cell line known as AlloStem™. AlloStem™ is a cell line that is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Following FDA approval, the program – referred to as CELZ-201 – is now being utilized in an early type 1 diabetes clinical trial. It will continue to undergo development for the treatment of both type 1 and type 2 Diabetes.